Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00856 | MMAE-SMCC | 2021179-11-1 |
| MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate. | Inquiry | |
| BADC-00857 | MC-Val-Cit-PAB-vinblastine | 2055896-92-7 |
| MC-Val-Cit-PAB-vinblastine is a drug-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB. | Inquiry | |
| BADC-00860 | Mal-PEG2-VCP-Eribulin | 2130869-18-8 |
| Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates. | Inquiry | |
| BADC-00863 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 |
| DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-00864 | SC-VC-PAB-MMAE | 2259318-46-0 |
| SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB. | Inquiry | |
| BADC-00866 | Mal-Phe-C4-VC-PAB-MMAE | 2259318-51-7 |
| Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. | Inquiry | |
| BADC-00868 | DBCO-(PEG2-VC-PAB-MMAE)2 | 2259318-55-1 |
| DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. | Inquiry |
